Dual inhibition of HER2 in breast cancer treatment

摘要

In The Lancet, Jose Baselga and colleagues present results from the phase 3 NeoALLTO trial, a pivotal investigation of dual anti-HER2 therapy for neoadjuvant treatment of breast cancer. The investigators used a straightforward approach to assess whether combination treatment with the antibody trastuzumab and the tyrosine kinase inhibitor lapatinib was better than single-agent treatment. 455 women were randomised to treatment with trastuzumab, lapatinib, or both drugs combined for 6 weeks, followed by addition of paclitaxel for 12 weeks and subsequent surgery.